ArticleHereditary cancer in clinical practice2026
Renal cell carcinoma risk among individuals heterozygous for fumarate hydratase variants: further insights into genotype-phenotype correlations.
Article in Hereditary cancer in clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFH-tumor predisposition syndrome (FH-TPS) is an autosomal dominant cancer predisposition syndrome caused by the fumarate hydratase (FH) gene. FH was initially shown to cause hereditary leiomyomatosis and renal cell cancer (HLRCC), historically called Reed syndrome. More recently, certain germline FH variants have been linked to pheochromocytoma (PHEO) risk in individuals without features of HLRCC. Diagnosis of these apparently non-overlapping conditions, FH-TPS-PHEO and FH-TPS-HLRCC, has increased through application of broad hereditary cancer gene panels. Early HLRCC studies suggested high lifetime RCC risk; however, emerging data suggests RCC risk in FH-TPS-HLRCC is lower than previous estimates.
methodsIndividuals with likely pathogenic or pathogenic (LPV/PV) FH variants were identified in a large, ethnically diverse health system. Heterozygotes were classified as FH-TPS-PHEO, FH-TPS-HLRCC, or FH-ARC (autosomal recessive carrier for congenital fumarate hydratase deficiency without FH-TPS risk) based on variant phenotype-genotype prediction. Groups were evaluated for demographics, FH testing indications, FH-TPS-HLRCC related clinical features, and RCC. Cumulative RCC incidence was estimated via Aalen-Johansen estimator.
resultsAmong 279 individuals with LPV/PV in FH, 4 had FH-TPS-PHEO, 111 FH-TPS-HLRCC, and 164 FH-ARC. The FH-TPS-HLRCC and FH-ARC groups were approximately two-thirds female. FH-ARC was less ethnically diverse due to a common variant in Northern Europeans (c.1431_1433dup). One-third of FH-TPS-HLRCC individuals underwent testing for cancer-related indications unrelated to FH-TPS-HLRCC, and nearly 75% of these were women who had uterine leiomyomata suggestive of FH-TPS-HLRCC. One-quarter of FH-TPS-HLRCC individuals were diagnosed via cascade testing, 40% of whom had clinical features of FH-TPS-HLRCC. RCC occurred in nine patients (5 FH-TPS-HLRCC, 3 FH-ARC, 1 FH-TPS-PHEO). All RCCs in FH-TPS-HLRCC were FH-deficient and occurred at earlier average age than the sporadic RCC in other groups. Cumulative RCC incidence by age 70 was 7.3% (95% CI 2.1-15.3%) in FH-TPS-HLRCC and 2.6% (95% CI 0.0-7.1%) in FH-ARC. RCC risk before age 25 in FH-TPS-HLRCC was negligible.
conclusionsFH-TPS-HLRCC is underdiagnosed and RCC risk is lower than earlier HLRCC estimates. Many individuals are identified through broad hereditary cancer gene panel testing and exhibit less obvious manifestations such as uterine leiomyomata. Adult RCC surveillance is warranted in FH-TPS-HLRCC, but the need for pediatric screening merits further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.